Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WanburyBOM:524212 -2.68%67 Current Ratio is 1.19 as of Mar. 2026, which is 170% above its 10-year median of 0.44. GuruFocus rates BOM:524212 with a GF Score™ of 67/100 and a GF Value™ of ₹244.17 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 1,000 Drug Manufacturers companies, Wanbury ranks worse than 76.4% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Wanbury's current ratio for the quarter that ended in Mar. 2026 was 1.19.
Wanbury has a current ratio of 1.19. It generally indicates good short-term financial strength.
The historical rank and industry rank for Wanbury's Current Ratio or its related term are showing as below:
BOM:524212'
s Current Ratio Range Over the Past 10 Years
Min: 0.22 Med: 0.44 Max: 1.19
Current: 1.19
During the past 13 years, Wanbury's highest Current Ratio was 1.19. The lowest was 0.22. And the median was 0.44.
BOM:524212's Current Ratio is ranked worse than 76.4% of 1000
companies
in the Drug Manufacturers industry
Industry Median: 1.975
vs BOM:524212: 1.19
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Wanbury Current Ratio Related Terms
Wanbury Current Ratio Historical Data
* Premium members only.
The historical data trend for Wanbury's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Wanbury's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wanbury Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Wanbury's Current Ratio distribution charts can be found below:
* The bar in red indicates where Wanbury's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wanbury (BOM:524212) has a Current Ratio of 1.19 as of Mar. 2026. This is 170% above median its historical median of 0.44. Over the past decade, Wanbury's Current Ratio has ranged from 0.22 to 1.19. According to the industry distribution chart, Wanbury ranks #764 out of 1000 companies in the Drug Manufacturers industry, placing it in the top 76.4%.
Is Wanbury's Current Ratio too high?
Wanbury's current Current Ratio of 1.19 is 170% above median its 10-year median of 0.44. Over the past 10 years, this metric has ranged from a low of 0.22 to a high of 1.19. The Drug Manufacturers industry median Current Ratio is 1.98. Wanbury's value of 1.19 is 39.7% below this industry median. Based on the distribution chart, Wanbury ranks #764 out of 1000 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Wanbury has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wanbury's Current Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Wanbury ranks #764 out of 1000 companies for Current Ratio. This places Wanbury in the lower half of its industry. The industry median Current Ratio is 1.98. Wanbury's value of 1.19 is 39.7% below this benchmark. Historically, Wanbury's own Current Ratio has ranged from 0.22 to 1.19 over the past decade. While the company's 10-year median is 0.44 vs. the industry median of 1.98, Wanbury has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 1.98, based on 1,000 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wanbury's current Current Ratio of 1.19 is 39.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 1.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wanbury's current Current Ratio is 1.19, which is 170% above median its own 10-year median of 0.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wanbury stock overvalued right now?
Based on GuruFocus' analysis, Wanbury (BOM:524212) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹244.17, compared to a current price of ₹279.10 — trading 14.3% above its estimated fair value. The current Current Ratio is 1.19, which is 170% above median its 10-year median of 0.44 and 39.7% below the Drug Manufacturers industry median of 1.98. Wanbury's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Wanbury (BOM:524212), the current Current Ratio is 1.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wanbury (BOM:524212) Overvalued in 2026?
Based on GuruFocus' analysis, Wanbury stock appears to be overvalued.
The current stock price of ₹279.10 is trading 14.3% above its estimated GF Value™ of ₹244.17.
GuruFocus considers Wanbury to be Modestly Overvalued.
Key valuation signals for BOM:524212:
Current Ratio: 1.19 (170% above median its 10-year median of 0.44)
GF Value™: ₹244.17 vs. price of ₹279.10 (14.3% above fair value)
Industry Position: 39.7% below the Drug Manufacturers median (#764 of 1000)
No single metric tells the full story. See the BOM:524212 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wanbury Ltd is engaged in the business of pharmaceutical and related activities, including research. Some of the company's products include Cpink 50mg tablets, Rabiplus capsules, and Folinine softgels, among others. The company has one segment of activity, namely, Pharmaceuticals and related products. It generates revenue from contracts with customers through the sale of manufactured and traded goods. Geographically, key revenue is generated from outside India.
67GF Score
Get the complete analysis for BOM:524212
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524212 has been successfully added to your 
